Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

SCRI Development Innovations, LLC

Country

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme

Phase 1

Completed

Conditions: Glioblastoma Multiforme
Colorectal Cancer
Gliosarcoma
Renal Cell Carcinoma

Interventions: Drug: INC280
Biological: bevacizumab

First Posted Date: 2015-03-12

Last Posted Date: 2023-09-21

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 65

Registration Number: NCT02386826

Locations: 🇺🇸
Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
🇺🇸
Yale School of Medicine, New Haven, Connecticut, United States
🇺🇸
HCA Midwest - Kansas City, Kansas City, Missouri, United States

and more 2 locations

Sarah Cannon Outcomes Registry

Withdrawn

Conditions: Oncology

First Posted Date: 2015-02-05

Last Posted Date: 2023-12-05

Lead Sponsor: SCRI Development Innovations, LLC

Registration Number: NCT02356822

Locations: 🇺🇸
SCRI, Nashville, Tennessee, United States

Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer

Phase 2

Completed

Conditions: Gastroesophageal Cancer

Interventions: Drug: nab-paclitaxel
Biological: ramucirumab

First Posted Date: 2014-12-17

Last Posted Date: 2022-07-01

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 65

Registration Number: NCT02317991

Locations: 🇺🇸
Rocky Mountain Cancer Centers, Denver, Colorado, United States
🇺🇸
Florida Cancer Specialists-South, Fort Myers, Florida, United States
🇺🇸
Florida Hospital Cancer Institute, Orlando, Florida, United States

and more 8 locations

Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers

Phase 2

Completed

Conditions: Neuroendocrine Cancer

Interventions: Drug: Carfilzomib

First Posted Date: 2014-12-17

Last Posted Date: 2023-12-05

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 62

Registration Number: NCT02318784

Locations: 🇺🇸
Rocky Mountain Cancer Center, Denver, Colorado, United States
🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸
Florida Hospital Cancer Institute, Orlando, Florida, United States

and more 7 locations

Study of Trametinib and Nab-paclitaxel in Patients With Melanoma

Phase 1

Withdrawn

Conditions: Melanoma

Interventions: Drug: trametinib
Drug: nab-paclitaxel

First Posted Date: 2014-11-25

Last Posted Date: 2019-05-30

Lead Sponsor: SCRI Development Innovations, LLC

Registration Number: NCT02300935

Locations: 🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸
Florida Cancer Center, Sarasota, Florida, United States
🇺🇸
Tennessee Oncology PLLC, Nashville, Tennessee, United States

Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Everolimus
Drug: Exemestane
Drug: Tamoxifen
Drug: Fulvestrant
Drug: Anastrozole
Drug: Letrozole
Drug: Toremifine

First Posted Date: 2014-11-17

Last Posted Date: 2020-02-17

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 48

Registration Number: NCT02291913

Locations: 🇺🇸
Florida Cancer Specialists-South, Fort Myers, Florida, United States
🇺🇸
Memorial Cancer Center, Hollywood, Florida, United States
🇺🇸
Woodlands Medical Specialists, Pensacola, Florida, United States

and more 5 locations

Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

Phase 2

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: LDE225
Drug: Bortezomib

First Posted Date: 2014-10-02

Last Posted Date: 2017-02-16

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 7

Registration Number: NCT02254551

Locations: 🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸
Oncology Hematology Care, Cincinnati, Ohio, United States
🇺🇸
Tennessee Oncology, Chattanooga, Tennessee, United States

and more 2 locations

Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases

Phase 2

Completed

Conditions: Colorectal Neoplasms

Interventions: Device: SIR-Spheres
Drug: Regorafenib

First Posted Date: 2014-07-21

Last Posted Date: 2023-12-05

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 26

Registration Number: NCT02195011

Locations: 🇺🇸
Florida Cancer Specialists - North, Saint Petersburg, Florida, United States
🇺🇸
Research Medical Center, Kansas City, Missouri, United States
🇺🇸
Tennessee Oncology PLLC, Nashville, Tennessee, United States

Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: MLN9708

First Posted Date: 2014-06-20

Last Posted Date: 2020-02-27

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 9

Registration Number: NCT02168101

Locations: 🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸
Oncology Hematology Care, Cincinnati, Ohio, United States
🇺🇸
Tennessee Oncology PLLC, Nashville, Tennessee, United States

and more 1 locations

Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: Everolimus
Drug: Enzalutamide

First Posted Date: 2014-04-29

Last Posted Date: 2021-05-04

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 38

Registration Number: NCT02125084

Locations: 🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸
Florida Cancer Center, Saint Petersburg, Florida, United States
🇺🇸
Oncology Hematology Care Inc., Cincinnati, Ohio, United States

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy